Robotic partial nephrectomy for clinical stage T1 tumors: Experience in 42 cases. Issue 1 (31st October 2015)

• Record Type: Journal Article
• Authors: Ener, Kemal; Canda, Abdullah Erdem; Altinova, Serkan; Atmaca, Ali Fuat; Alkan, Erdal; Asil, Erem; Ozcan, Muhammet Fuat; Akbulut, Ziya; Balbay, Mevlana Derya
• Is Part Of: Kaohsiung journal of medical sciences. Volume 32:Issue 1(2016)
• Page Start: 16
• Page End: 21
• Publication Date: 2015-10-31
• Subjects: Partial nephrectomy -- Renal cell carcinoma -- Robotics; Medicine -- Periodicals; 610.5
• DOI: 10.1016/j.kjms.2015.09.008
• Languages: English
• ISSNs: 1607-551X

Abstract

Abstract: The aim of this study was to evaluate outcomes of robotic partial nephrectomy (RAPN) procedures. At two centers, 42 patients underwent RAPN. Radius, Exo/Endophytic, Nearness, Anterior/Posterior, Location (R.E.N.A.L.) nephrometry and PADUA scores of patients were calculated by computed tomography (CT) or magnetic resonance imaging (MRI). Intra‐ and perioperative (0–30 days) complications were evaluated using modified Clavien classification. A four‐arm da Vinci‐S robotic surgical system was used and outcomes were evaluated retrospectively. Mean age of the patients was 52.3 ± 6.5 years. Mean tumor size was 3.1 ± 1.0 (1.4–6.6) cm. R.E.N.A.L. nephrometry and PADUA scores were 6.0 ± 1.5 and 7.5 ± 0.9, respectively. Mean surgical time was 127.7 ± 18.7 minutes and estimated blood loss was 100 ± 18.1 cc. Mean warm ischemia time was 16.0 ± 8.9 (0–30) minutes. Intraoperative complications did not develop in any patient. Median hospital stay was 3.0 (2–6) days. Except for 17 patients, hilar clamping was performed in 25 patients. Histopathology results included 34 renal cell carcinoma (22 clear cell, 7 chromophobe cell, 4 papillary cell, and 1 clear papillary cell). Oncocytoma ( n = 4), adenoma ( n = 1), fibroadipose tissue ( n = 1), papillary epithelial hyperplasia ( n = 1), and chronic pyelonephritis ( n = 1) were present. Surgical margins were negative in all patients. During a median follow‐up period of 15.5 ± 10.9 (3–46) months, neither local recurrence nor distant metastasis was detected. In conclusion, RAPN is a safe, minimally invasive surgical approach, with excellent surgical and oncological outcomes in T1 kidney tumors. Zero ischemia off‐clamp RAPN is also safe in selected masses with the advantage of avoiding complete renal ischemia.